
A 16-week study on iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes showed increased time in range from 26.4% to 52.7%. Patient-reported treatment satisfaction also improved across well-being, medical control, lifestyle, and convenience. While the association between glycemic control and satisfaction was weak, overall treatment perception was positive.
Like
Save
Share